 Cellectis Euronext Growth: ALCLS; Nasdaq: CLLS, a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells UCART, today announced the appointment of Leopold Bertea, Ph.D., to the role of Senior Vice President of Technical Operations - Europe. Dr. Bertea is based in the Cellectis Paris office and reports to Bill Monteith, Executive Vice President, Technical Operations. 